We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.07% | 97.27 | 97.91 | 97.07 | 97.75 | 1,045,674 | 01:00:00 |
From May 2019 to May 2024
--Novartis AG (NVS) said it would supply U.S. pharmacies with its pre-filled Symjepi epinephrine shots, amid a shortage of Mylan NV's (MYL) EpiPens, Reuters reports Tuesday.
--Novartis said they would charge a wholesale price of $250 for two adult-dose syringes, the report said, adding Mylan charges $300 for its authorized generic.
--A unit of Pfizer Inc. (PFE) produces all EpiPens sold across the globe at a single plant, which had been experiencing manufacturing problems, the report said.
Full story: https://www.reuters.com/article/us-novartis-epipen-launch/novartis-to-sell-epinephrine-shot-in-u-s-pharmacies-amid-epipen-shortage-idUSKCN1U418X
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
July 09, 2019 19:15 ET (23:15 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
